Some stocks get crushed because the business is broken. Others get crushed because the hype got way ahead of itself. This company looks more like the second bucket right now.
The stock has been absolutely smoked from its highs, but the actual business is still putting up strong growth, improving profitability, and attracting fresh support from analysts.
Simplify AI Investing (Sponsored)
Your inbox is flooded with newsletters. Your feed is chaos. Somewhere in that noise are the insights that could transform your work—but who has time to find them?
The Deep View solves this. We read everything, analyze what matters, and deliver only the intelligence you need.
No duplicate stories, no filler content, no wasted time. Just the essential AI developments that impact your industry, explained clearly and concisely.
With five focused minutes. While others scramble to keep up, you'll stay ahead of developments that matter.
600,000+ professionals at top companies have already made this switch.
Join them today, for free.
What Just Happened
GeneDx Holdings (NASDAQ: WGS) has been getting a little love from the analyst crowd again, and for once, it is not just empty cheerleading.
WGS was recently upgraded to a Strong Buy from Zacks, pointing to rising earnings estimates as a sign that the company’s business outlook is improving.
That matters because estimate revisions tend to be one of the cleaner signals for near-term stock momentum, especially in names that have already been beaten up badly.
There was also another supportive note from Canaccord Genuity, which reiterated its Buy rating and kept a $170 price target after GeneDx reported fourth-quarter results.
Revenue came in at $121 million, up 27% year over year.
More importantly, its core WES and WGS revenue reached $104 million, up 32% year over year, while total test volume rose 9% and WES and WGS test volume jumped 34%.
That is the key point here. The stock may look ugly, but the operating trends are not acting like a company in full collapse.
Revenue is still growing, core volume is still climbing, and margins are moving in the right direction.
The Business People Probably Skip Over Too Fast
GeneDx lives in the world of genetic testing, with a big focus on whole exome sequencing and whole genome sequencing.
That is not exactly the kind of story that gets explained well in a casual scroll through a watchlist, but the broad idea is simple enough.
The company helps doctors and healthcare systems use advanced genetic testing to better diagnose rare diseases and other complex conditions.
That may sound niche, but niche can be very profitable when the clinical value is high.
The bigger pitch is that GeneDx is not just selling tests. It is trying to build a stronger position in a category that could become increasingly important as precision medicine keeps moving forward.
If genetic testing becomes more central to diagnosis and treatment decisions over time, then a company with scale, data, and established relationships could end up with a nice seat at the table.
That is why this name is interesting. It is not just a random lab stock hoping for a lucky quarter.
It has exposure to a real long-term healthcare trend, and the market may be starting to remember that after punishing the shares.
Poll: How do you primarily consume financial news?
Before The Open (Sponsored)
Every day before 6AM, Matthew Tuttle sits down at his trading desk in Connecticut to write to you about hedges, edges, asymmetric opportunities and themes in the market.
Get his free Daily H.E.A.T. email for a dose of actionable market insight every weekday morning.
Why The Story Still Has Life
There are really three things helping this one.
First, the core growth engine is still working. WES and WGS revenue rose 32% year over year, and the associated test volume climbed 34%.
For a company whose stock is down hard, those are not exactly numbers that scream broken business. They suggest demand is still there and the company is still gaining traction where it matters most.
Second, profitability is improving.
Adjusted gross margin hit 71.1%, up 900 basis points from a year earlier, and GeneDx posted positive adjusted net income of $4.4 million, or $0.14 per diluted share.
That is important because investors are a lot less patient with healthcare growth stories than they used to be. Growth alone is nice, but growth with improving margins gets taken much more seriously.
Third, the 2026 outlook still looks healthy. The company reiterated revenue guidance of $540 million to $555 million for 2026, which implies growth of 26% to 30% year over year.
It also maintained expectations for WES and WGS revenue growth of 33% to 35%, volume growth of 33% to 35%, gross margin of at least 70%, and positive adjusted net income.
That is not a company waving its arms and begging investors to believe. That is a company laying out a pretty concrete case that the growth story is still intact.
Want to make sure you never miss a stock recommendation?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.
Why The Stock Could Actually Work From Here
The obvious bull case is that this has turned into one of those rare situations where the stock got punished harder than the business deserved.
WGS is down more than 30% over the past year and massively below its 52-week high. That means expectations have already been wrung out to a degree.
When that happens, the setup can get interesting if the company keeps executing, because the bar becomes much easier to clear.
There is also the simple earnings revision angle. Zacks did not upgrade the name for fun. The upgrade was tied to rising estimates, which often gets institutional investors paying closer attention.
When earnings expectations start moving up, valuation models move up too, and that can be enough to bring buyers back into a stock that had fallen out of favor.
Then there is the analyst price target gap. A $170 target versus a stock around $60 is the kind of spread that tells you there is still a camp out there that thinks the market is badly underpricing the business.
That does not mean the target is right, but it does mean the upside case is not some tiny squeeze for scraps. If this story gets back in favor, the move could be meaningful.
A New Frontier (Sponsored)
He revived EVs, revolutionized space, and built the biggest satellite network.
But this AI tech could go down in history as the crown jewel of Elon's career.
Nvidia CEO Jensen Huang says, "What Elon and his team has achieved is singular. It's never been done before."
Get the full story here.
What Could Go Wrong
Of course, if this were all easy, the stock would not be sitting down here.
The first risk is that growth slows faster than expected. Genetic testing is a strong theme, but investors are paying attention to execution now, not just dreams.
If volume growth cools, pricing weakens, or reimbursement trends get messy, sentiment could sour quickly.
The second risk is that average selling prices continue to slip. WES and WGS average selling price was about $3,746 in the quarter, down both quarter over quarter and year over year.
That is not catastrophic on its own, especially if volumes keep rising, but it is something to watch. A growth story looks a lot prettier when both volume and pricing cooperate.
The third risk is that the market just stays grumpy. A lot of smaller healthcare and diagnostics names have had a hard time winning investor trust back once momentum breaks.
Sometimes the business improves and the stock still sits there like a lump for longer than anyone wants.
And finally, this is still a company without the broad cushion of a giant diversified healthcare empire behind it.
That means execution matters a lot. A few bad quarters can change the story fast.
What I’d Watch Next
For the next couple of quarters, the checklist is pretty simple.
Watch WES and WGS revenue growth. Watch test volume growth. Watch whether gross margins stay above 70%.
Watch average selling price to make sure it is not eroding too quickly. And watch whether earnings estimates keep moving up.
If those boxes keep getting checked, the stock has a decent shot at rebuilding credibility.
My Take
GeneDx feels like one of those names the market got tired of before the actual business finished improving.
That does not make it a slam dunk. The stock has clearly burned people, and when a chart looks this ugly, investors tend to need a lot of proof before they forgive it. But the setup is still pretty compelling.
Core revenue is growing nicely, margins are getting better, profitability is improving, and the 2026 outlook still looks strong.
The clean bull case is not complicated.
GeneDx keeps growing its core testing business, continues proving it can do that profitably, and the market slowly realizes this is not just a busted hype stock.
It may not rocket back to old highs overnight, but from down here, it does not need perfection to start looking a lot more interesting.
This one may not be healthy-looking yet on the chart, but the business itself still has a pulse.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
